1
|
Zhang Q, Lin J, Yang M, Li Z, Zhang M, Bu B. Therapeutic potential of natural killer cells in neuroimmunological diseases. Biomed Pharmacother 2024; 173:116371. [PMID: 38430631 DOI: 10.1016/j.biopha.2024.116371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2023] [Revised: 02/27/2024] [Accepted: 02/28/2024] [Indexed: 03/05/2024] Open
Abstract
Natural killer (NK) cells, a major component of the innate immune system, have prominent immunoregulatory, antitumor proliferation, and antiviral activities. NK cells act as a double-edged sword with therapeutic potential in neurological autoimmunity. Emerging evidence has identified NK cells are involved in the development and progression of neuroimmunological diseases such as multiple sclerosis, neuromyelitis optica spectrum disorders, autoimmune encephalitis, Guillain-Barré Syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, and idiopathic inflammatory myopathy. However, the regulatory mechanisms and functional roles of NK cells are highly variable in different clinical states of neuroimmunological diseases and need to be further determined. In this review, we summarize the evidence for the heterogenic involvement of NK cells in the above conditions. Further, we describe cutting-edge NK-cell-based immunotherapy for neuroimmunological diseases in preclinical and clinical development and highlight challenges that must be overcome to fully realize the therapeutic potential of NK cells.
Collapse
Affiliation(s)
- Qing Zhang
- Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Jing Lin
- Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Mengge Yang
- Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Zhijun Li
- Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan 430030, China.
| | - Min Zhang
- Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan 430030, China.
| | - Bitao Bu
- Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan 430030, China.
| |
Collapse
|
2
|
Takimoto R, Kamigaki T, Ito H, Saito M, Takizawa K, Soejima K, Yasuda H, Ohgino K, Terai H, Tomita K, Miura M, Mizukoshi E, Miyashita T, Nakamoto Y, Hayashi K, Miwa S, Kitahara M, Takeuchi A, Kimura H, Mochizuki T, Sugie H, Seino KI, Yamada T, Takeuchi S, Makita K, Naitoh K, Yasumoto K, Yoshida Y, Inoue H, Kotake K, Ohshima K, Noda SE, Okamoto M, Yoshimoto Y, Okada S, Ibe H, Oguma E, Goto S. Safety evaluation of immune-cell therapy for malignant tumor in the Cancer Immune-cell Therapy Evaluation Group (CITEG). Cytotherapy 2023; 25:1229-1235. [PMID: 37486281 DOI: 10.1016/j.jcyt.2023.06.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Revised: 06/10/2023] [Accepted: 06/22/2023] [Indexed: 07/25/2023]
Abstract
BACKGROUND AIMS With the aim of strengthening the scientific evidence of immune-cell therapy for cancer and further examining its safety, in October 2015, our hospital jointly established the Cancer Immune-Cell Therapy Evaluation Group (CITEG) with 39 medical facilities nationwide. METHODS Medical information, such as patients' background characteristics, clinical efficacy and therapeutic cell types obtained from each facility, has been accumulated, analyzed and evaluated by CITEG. In this prospective study, we analyzed the adverse events associated with immune-cell therapy until the end of September 2022, and we presented our interim safety evaluation. RESULTS A total of 3839 patients with malignant tumor were treated with immune-cell therapy, with a median age of 64 years (range, 13-97 years) and a male-to-female ratio of 1:1.08 (1846:1993). Most patients' performance status was 0 or 1 (86.8%) at the first visit, and 3234 cases (84.2%) were advanced or recurrent cases, which accounted for the majority. The total number of administrations reported in CITEG was 31890, of which 960 (3.0%) showed adverse events. The numbers of adverse events caused by treatment were 363 (1.8%) of 19661 administrations of αβT cell therapy, 9 of 845 administrations of γδT-cell therapy (1.1%) and 10 of 626 administrations of natural killer cell therapy (1.6%). The number of adverse events caused by dendritic cell (DC) vaccine therapy was 578 of 10748 administrations (5.4%), which was significantly larger than those for other treatments. Multivariate analysis revealed that αβT cell therapy had a significantly greater risk of adverse events at performance status 1 or higher, and patients younger than 64 years, women or adjuvant immune-cell therapy had a greater risk of adverse events in DC vaccine therapy. Injection-site reactions were the most frequently reported adverse events, with 449 events, the majority of which were associated with DC vaccine therapy. Among all other adverse events, fever (228 events), fatigue (141 events) and itching (131 events) were frequently reported. In contrast, three patients had adverse events (fever, abdominal pain and interstitial pneumonia) that required hospitalization, although they were weakly related to this therapy; rather, it was considered to be the effect of treatment for the primary disease. CONCLUSIONS Immune-cell therapy for cancer was considered to be a safe treatment without serious adverse events.
Collapse
Affiliation(s)
- Rishu Takimoto
- Seta Clinic Group, Tokyo, Japan; Next Generation Cell and Immunotherapy, Advanced Research Institute for Health Science, Juntendo University, Tokyo, Japan; LSI Sapporo Clinic, Sapporo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan.
| | - Takashi Kamigaki
- Seta Clinic Group, Tokyo, Japan; Next Generation Cell and Immunotherapy, Advanced Research Institute for Health Science, Juntendo University, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Hisao Ito
- Seta Clinic Group, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Masashi Saito
- Seta Clinic Group, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Ken Takizawa
- Seta Clinic Group, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Kenzo Soejima
- Seta Clinic Group, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Hiroyuki Yasuda
- Seta Clinic Group, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Keiko Ohgino
- Seta Clinic Group, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Hideki Terai
- Seta Clinic Group, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Katsuro Tomita
- Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Miyabi Miura
- Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Eishiro Mizukoshi
- Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Tomoharu Miyashita
- Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Yasunari Nakamoto
- Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Katsuhiro Hayashi
- Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Shinji Miwa
- Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Masaaki Kitahara
- Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Akihiko Takeuchi
- Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Hiroaki Kimura
- Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Takafumi Mochizuki
- Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Hiroki Sugie
- LSI Sapporo Clinic, Sapporo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Ken-Ichiro Seino
- LSI Sapporo Clinic, Sapporo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Tomonori Yamada
- LSI Sapporo Clinic, Sapporo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Syuhei Takeuchi
- LSI Sapporo Clinic, Sapporo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Kaori Makita
- Kitaosaka Medical Clinic, Suita City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Keiko Naitoh
- Fukuoka Medical Clinic, Fukuoka City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Kosei Yasumoto
- Fukuoka Medical Clinic, Fukuoka City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Yoichiro Yoshida
- Fukuoka Medical Clinic, Fukuoka City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Hiroyuki Inoue
- Fukuoka Medical Clinic, Fukuoka City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Katsuhiro Kotake
- Masuko Memorial Hospital, Nagoya City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Kihachi Ohshima
- Heisei-Hidaka Clinic, Gunma, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Shin-Ei Noda
- Heisei-Hidaka Clinic, Gunma, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Masahiko Okamoto
- Heisei-Hidaka Clinic, Gunma, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Yuya Yoshimoto
- Heisei-Hidaka Clinic, Gunma, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Sachiko Okada
- Seta Clinic Group, Tokyo, Japan; Next Generation Cell and Immunotherapy, Advanced Research Institute for Health Science, Juntendo University, Tokyo, Japan
| | - Hiroshi Ibe
- Seta Clinic Group, Tokyo, Japan; Next Generation Cell and Immunotherapy, Advanced Research Institute for Health Science, Juntendo University, Tokyo, Japan
| | - Eri Oguma
- Seta Clinic Group, Tokyo, Japan; Next Generation Cell and Immunotherapy, Advanced Research Institute for Health Science, Juntendo University, Tokyo, Japan
| | - Shigenori Goto
- Seta Clinic Group, Tokyo, Japan; Next Generation Cell and Immunotherapy, Advanced Research Institute for Health Science, Juntendo University, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| |
Collapse
|
3
|
Fousek K, Horn LA, Qin H, Dahut M, Iida M, Yacubovich D, Hamilton DH, Thomas A, Schlom J, Palena C. An Interleukin-15 Superagonist Enables Antitumor Efficacy of Natural Killer Cells Against All Molecular Variants of SCLC. J Thorac Oncol 2023; 18:350-368. [PMID: 36410696 PMCID: PMC9974560 DOI: 10.1016/j.jtho.2022.11.008] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2022] [Revised: 11/02/2022] [Accepted: 11/03/2022] [Indexed: 11/23/2022]
Abstract
INTRODUCTION SCLC is a highly aggressive tumor with a 5-year survival rate of less than 6%. A heterogeneous disease, SCLC is classified into four subtypes that include tumors with neuroendocrine and non-neuroendocrine features. Immune checkpoint blockade has been recently added for the frontline treatment of SCLC; however, this therapy has only led to modest clinical improvements. The lack of clinical benefit in a cancer type known to have a high tumor mutational burden has been attributed to poor T-cell infiltration and low expression of MHC-class I in most SCLC tumors. In an attempt to devise a more effective immunotherapeutic regimen, this study investigated an alternate approach on the basis of the use of the clinical-stage interleukin-15 superagonist, N-803. METHODS Preclinical models of SCLC spanning all molecular subtypes were used to evaluate the susceptibility of SCLC to natural killer (NK)-mediated lysis in vitro, including NK cells activated by N-803. Antitumor activity of N-803 was evaluated in vivo with a xenograft model of SCLC. RESULTS In vitro and in vivo data revealed differences in susceptibility of SCLC subtypes to lysis by NK cells and that NK cells activated by N-803 effectively lyse SCLC tumor cells across all variant subtypes, regardless of their expression of MHC-class I. CONCLUSIONS These findings highlight the potential of a novel immune-based intervention using a cytokine-based therapeutic option for the treatment of SCLC. We hypothesize that N-803 may provide benefit to most patients with SCLC, including those with immunologically cold tumors lacking MHC expression.
Collapse
Affiliation(s)
- Kristen Fousek
- Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Lucas A. Horn
- Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Haiyan Qin
- Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Madeline Dahut
- Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Masafumi Iida
- Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Dan Yacubovich
- Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Duane H. Hamilton
- Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Anish Thomas
- Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Jeffrey Schlom
- Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Claudia Palena
- Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
| |
Collapse
|
4
|
Abstract
Immunotherapy in cancer takes advantage of the exquisite specificity, potency, and flexibility of the immune system to eliminate alien tumor cells. It involves strategies to activate the entire immune defense, by unlocking mechanisms developed by tumor cells to escape from surrounding immune cells, as well as engineered antibody and cellular therapies. What is important to note is that these are therapeutics with curative potential. The earliest example of immune therapy is allogeneic stem cell transplantation, introduced in 1957, which is still an important modality in hematology, most notably in myeloid malignancies. In this review, we discuss developmental trends of immunotherapy in hematological malignancies, focusing on some of the strategies that we believe will have the most impact on future clinical practice in this field. In particular, we delineate novel developments for therapies that have already been introduced into the clinic, such as immune checkpoint inhibition and chimeric antigen receptor T-cell therapies. Finally, we discuss the therapeutic potential of emerging strategies based on T-cell receptors and adoptive transfer of allogeneic natural killer cells.
Collapse
Affiliation(s)
- Luca Mazzarella
- Department of Experimental Oncology, European Institute of Oncology, Milano, Italy
| | - Gunilla Enblad
- Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology, Uppsala University, Sweden
| | - Johanna Olweus
- Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.,Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Karl-Johan Malmberg
- Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.,Institute of Clinical Medicine, University of Oslo, Oslo, Norway.,Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Mats Jerkeman
- Department of Oncology, Skane University Hospital, Lund University, Lund, Sweden
| |
Collapse
|